The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer’s disease

  • Sofie M. Adriaanse
  • Koene R. A. van Dijk
  • Rik Ossenkoppele
  • Martin Reuter
  • Nelleke Tolboom
  • Marissa D. Zwan
  • Maqsood Yaqub
  • Ronald Boellaard
  • Albert D. Windhorst
  • Wiesje M. van der Flier
  • Philip Scheltens
  • Adriaan A. Lammertsma
  • Frederik Barkhof
  • Bart N. M. van Berckel
Original Article

Abstract

Purpose

The present multimodal neuroimaging study examined whether amyloid pathology and glucose metabolism are related to cortical volume loss over time in Alzheimer’s disease (AD) patients and healthy elderly controls.

Methods

Structural MRI scans of eleven AD patients and ten controls were available at baseline and follow-up (mean interval 2.5 years). Change in brain structure over time was defined as percent change of cortical volume within seven a-priori defined regions that typically show the strongest structural loss in AD. In addition, two PET scans were performed at baseline: [11C]PIB to assess amyloid-β plaque load and [18F]FDG to assess glucose metabolism. [11C]PIB binding and [18F]FDG uptake were measured in the precuneus, a region in which both amyloid deposition and glucose hypometabolism occur early in the course of AD.

Results

While amyloid-β plaque load at baseline was not related to cortical volume loss over time in either group, glucose metabolism within the group of AD patients was significantly related to volume loss over time (rho = 0.56, p < 0.05).

Conclusion

The present study shows that in a group of AD patients amyloid-β plaque load as measured by [11C]PIB behaves as a trait marker (i.e., all AD patients showed elevated levels of amyloid, not related to subsequent disease course), whilst hypometabolism as measured by [18F]FDG changed over time indicating that it could serve as a state marker that is predictive of neurodegeneration.

Keywords

Alzheimer’s disease Amyloid plaques Hypometabolism Atrophy Longitudinal study 

Notes

Acknowledgments

This study was sponsored by Internationale Stichting Alzheimer Onderzoek (ISAO; project number #11539) and Hersenstichting Nederland (KS2011(1)-24).

We thank the support of the Athinoula A. Martinos Center for Biomedical Imaging at MGH including analysis methods developed by NIH grant P41RR14075.

Disclosure statement

Dr. Van Berckel receives research support from the American Health Assistance Foundation, Alzheimer Association, Internationale Stichting Alzheimer Onderzoek, the Center of Translational Molecular Medicine and the Dutch Organisation for Scientific Research.

Dr. Barkhof serves on the editorial boards of Brain, European Radiology, the Journal of Neurology, Neurosurgery & Psychiatry, the Journal of Neurology, Multiple Sclerosis and Neuroradiology and serves as a consultant for Bayer-Schering Pharma, Sanofi-Aventis, Biogen-Idec, UCB, Merck-Serono, Jansen Alzheimer Immunotherapy, Baxter, Novartis and Roche.

Dr. Scheltens serves/has served on the advisory boards of: Genentech, Novartis, Roche, Danone, Nutricia, Baxter and Lundbeck. He has been a speaker at symposia organised by Lundbeck, Merz, Danone, Novartis, Roche and Genentech. For all his activities he receives no personal compensation. He serves on the editorial board of Alzheimer’s Research & Therapy and Alzheimer Disease and Associated Disorders, is a member of the scientific advisory board of the EU Joint Programming Initiative and the French National Plan Alzheimer.

Dr. Reuter receives funding from several grants: NINDS 5R01NS052585-05, NIBIB 5R01EB006758-04, NINDS 2-R01-NS042861-06A1, NINDS 5-P01-NS058793-03, and NICHD R01-HD071664.

There are no other actual or potential conflicts of interest to disclose. All authors have read and agreed with the contents of the manuscript. The results of the study have not been published before and they are not under consideration to be published by another journal.

References

  1. 1.
    Jack Jr CR. Alliance for aging research AD biomarkers work group: structural MRI. Neurobiol Aging. 2011;32 Suppl 1:S48–57.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Jack Jr CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207–16.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Caroli A, Frisoni GB. The dynamics of Alzheimer’s disease biomarkers in the Alzheimer’s Disease Neuroimaging Initiative cohort. Neurobiol Aging. 2010;31:1263–74.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Frisoni GB, Fox NC, Jack Jr CR, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6:67–77.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Fjell AM, Walhovd KB. New tools for the study of Alzheimer’s disease: what are biomarkers and morphometric markers teaching us? Neuroscientist. 2011;17:592–605.PubMedCrossRefGoogle Scholar
  6. 6.
    Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19.PubMedCrossRefGoogle Scholar
  8. 8.
    Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol. 2009;21:117–28.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Tolboom N, Yaqub M, van der Flier WM, et al. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med. 2009;50:191–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Jack Jr CR, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain. 2009;132:1355–65.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Ossenkoppele R, Tolboom N, Foster-Dinsley J, et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging. 2012;39:990–1000.PubMedCrossRefGoogle Scholar
  12. 12.
    Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain. 2006;129:2856–66.PubMedCrossRefGoogle Scholar
  13. 13.
    Villain N, Chetelat G, Grassiot B, et al. Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: a voxelwise PiB-PET longitudinal study. Brain. 2012;135:2126–39.PubMedCrossRefGoogle Scholar
  14. 14.
    Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69:181–92.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Rocher AB, Chapon F, Blaizot X, Baron JC, Chavoix C. Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage. 2003;20:1894–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Schwartz WJ, Smith CB, Davidsen L, Savaki H, Sokoloff L, Mata M, et al. Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. Science. 1979;205:723–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Drzezga A, Becker JA, Van Dijk KR, et al. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain. 2011;134:1635–46.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Li Y, Rinne JO, Mosconi L, et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2008;35:2169–81.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Mosconi L, Sorbi S, de Leon MJ, et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer’s disease. J Nucl Med. 2006;47:1778–86.PubMedGoogle Scholar
  20. 20.
    Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30:1104–13.PubMedCrossRefGoogle Scholar
  21. 21.
    Folstein MF, Robins LN, Helzer JE. The mini-mental state examination. Arch Gen Psychiatry. 1983;40:812.PubMedCrossRefGoogle Scholar
  22. 22.
    Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Brix G, Zaers J, Adam LE, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med. 1997;38:1614–23.PubMedGoogle Scholar
  25. 25.
    Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage. 2012;61:1402–18.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Sabuncu MR, Desikan RS, Sepulcre J, et al. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol. 2011;68:1040–8.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Fischl B, Sereno MI, Tootell RB, Dale AM. High-resolution intersubject averaging and a coordinate system for the cortical surface. Hum Brain Mapp. 1999;8:272–84.PubMedCrossRefGoogle Scholar
  28. 28.
    Whitwell JL, Jack Jr CR. Comparisons between Alzheimer disease, frontotemporal lobar degeneration, and normal aging with brain mapping. Top Magn Reson Imaging. 2005;16:409–25.PubMedCrossRefGoogle Scholar
  29. 29.
    Svarer C, Madsen K, Hasselbalch SG, et al. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage. 2005;24:969–79.PubMedCrossRefGoogle Scholar
  30. 30.
    Nissen IA, Boellaard R, Ossenkoppele R et al. Impact of partial volume corrections on quantitative brain PET studies [abstract]. SNM Conference 2012.Google Scholar
  31. 31.
    Teo BK, Seo Y, Bacharach SL, Carrasquillo JA, Libutti SK, Shukla H, et al. Partial-volume correction in PET: validation of an iterative postreconstruction method with phantom and patient data. J Nucl Med. 2007;48:802–10.PubMedGoogle Scholar
  32. 32.
    Wu Y, Carson RE. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab. 2002;22:1440–52.PubMedCrossRefGoogle Scholar
  33. 33.
    Yaqub M, Tolboom N, Boellaard R, van Berckel BN, van Tilburg EW, Luurtsema G, et al. Simplified parametric methods for [11C]PIB studies. Neuroimage. 2008;42:76–86.PubMedCrossRefGoogle Scholar
  34. 34.
    Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Nakazato Y. Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by beta protein immunostain. Acta Neuropathol. 1989;77:314–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging. 2001;20(1):45–57.PubMedCrossRefGoogle Scholar
  36. 36.
    Chetelat G, Villemagne VL, Bourgeat P, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol. 2010;67(3):317–24.PubMedGoogle Scholar
  37. 37.
    Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Abeta[42] correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65(2):176–83.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357–67.PubMedCrossRefGoogle Scholar
  39. 39.
    Tosun D, Schuff N, Mathis CA, Jagust W, Weiner MW. Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain. 2011;134(Pt 4):1077–88.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132(Pt 5):1310–23.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Andrews KA, Modat M, Macdonald KE, et al. Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials. PLoS One. 2013;8(3):e58816.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Driscoll I, Zhou Y, An Y, et al. Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals. Neurobiol Aging. 2011;32(12):2123–30.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Josephs KA, Whitwell JL, Ahmed Z, et al. Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol. 2008;63(2):204–12.PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Chetelat G, Villemagne VL, Villain N, et al. Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition. Neurology. 2012;78(7):477–84.PubMedCrossRefGoogle Scholar
  45. 45.
    Doré V, Villemange VL, Bourgeat P, et al. Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. JAMA Neurol. 2013;70(7):903–11.PubMedCrossRefGoogle Scholar
  46. 46.
    DeSanti S, de Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging. 2001;22(4):529–39.CrossRefGoogle Scholar
  47. 47.
    Jagust W, Gitcho A, Sun F, Kuczynski B, Mungas D, Haan M. Brain imaging evidence of preclinical Alzheimer’s disease in normal aging. Ann Neurol. 2006;59(4):673–81.PubMedCrossRefGoogle Scholar
  48. 48.
    Meguro K, LeMestric C, Landeau B, Eustache F, Baron J-C. Relations between hypometabolism in the posterior association neocortex and hippocampal atrophy in alzheimer’s disease: a PET/MRI correlative study. J Neurol Neurosurg Psychiatry. 2001;71:315–21.PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Yamaguchi S, Meguro K, Itoh M, et al. Decreased cortical glucose metabolism correlates with hippocampal atrophy in Alzheimer’s disease as shown by MRI and PET. J Neurol Neurosurg Psychiatry. 1997;62:596–600.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Chetelat G, Desgranges B, Landeau B, Mezenge F, Poline JB, de la Sayette V, et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer’s disease. Brain. 2008;131:60–71.PubMedCrossRefGoogle Scholar
  51. 51.
    Förster S, Grimmer T, Miederer I, et al. Regional expansion of hypometabolism in Alzheimer’s disease follows amyloid deposition with temporal delay. Biol Psychiatry. 2012;71:792–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Knopman DS, Jack Jr CR, Wiste HJ, et al. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis. JAMA Neurol. 2013;70(8):1030–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Cohen AD, Price JC, Weissfeld LA, et al. Basal cerebral metabolism may modulate the cognitive effects of aβ in mild cognitive impairment: an example of brain reserve. J Neurosci. 2009;29(47):14770–8.PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    Förster S, Yousefi BH, Wester HJ, et al. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2012;39(12):1927–37.PubMedCrossRefGoogle Scholar
  55. 55.
    Cirrito JR, Kang JE, Lee J, et al. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008;58:42–51.PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Briellmann RS, Syngeniotis A, Jackson GD. Comparison of hippocampal volumetry at 1.5 Tesla and at 3 Tesla. Epilepsia. 2001;42(8):1021–4.PubMedCrossRefGoogle Scholar
  57. 57.
    Scorzin JE, Kaaden S, Quesada CM, Müller CA, Fimmers R, Urbach H, et al. Volume determination of amygdale and hippocampus at 1.5 and 3.0 T MRI in temporal lobe epilepsy. Epilepsy Res. 2008;82(1):29–37.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Sofie M. Adriaanse
    • 1
    • 8
  • Koene R. A. van Dijk
    • 2
    • 5
  • Rik Ossenkoppele
    • 3
  • Martin Reuter
    • 5
    • 6
  • Nelleke Tolboom
    • 3
  • Marissa D. Zwan
    • 3
  • Maqsood Yaqub
    • 4
  • Ronald Boellaard
    • 4
  • Albert D. Windhorst
    • 4
  • Wiesje M. van der Flier
    • 7
  • Philip Scheltens
    • 7
  • Adriaan A. Lammertsma
    • 4
  • Frederik Barkhof
    • 3
  • Bart N. M. van Berckel
    • 3
  1. 1.Department of Radiology and Nuclear MedicineVU University Medical CenterAmsterdamThe Netherlands
  2. 2.Department of Psychology, Center for Brain ScienceHarvard UniversityCambridgeUSA
  3. 3.Department of Radiology and Nuclear Medicine, Alzheimer Center, Neuroscience Campus AmsterdamVU University Medical CenterAmsterdamThe Netherlands
  4. 4.Department of Radiology and Nuclear Medicine, Neuroscience Campus AmsterdamVU University Medical CenterAmsterdamThe Netherlands
  5. 5.Athinoula A. Martinos Center for Biomedical ImagingMassachusetts General HospitalCharlestownUSA
  6. 6.Computer Science and Artificial Intelligence Laboratory, Division of Health Sciences and TechnologyMassachusetts Institute of TechnologyCambridgeUSA
  7. 7.Department of Neurology, Alzheimer Center, Neuroscience Campus AmsterdamVU University Medical CenterAmsterdamThe Netherlands
  8. 8.Department of Radiology and Nuclear Medicine, Alzheimer Center, Neuroscience Campus AmsterdamVU University Medical CenterAmsterdamThe Netherlands

Personalised recommendations